

Christophe Schmitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1437812/publications.pdf>

Version: 2024-02-01

33
papers

2,920
citations

430874

18
h-index

395702

33
g-index

33
all docs

33
docs citations

33
times ranked

2019
citing authors

#	ARTICLE	IF	CITATIONS
1	A Model-Based Framework to Inform the Dose Selection and Study Design of Efficizumab for Pediatric Patients With Hemophilia A. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 232-244.	2.0	7
2	Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12670.	2.3	24
3	Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study. <i>Arthritis Research and Therapy</i> , 2022, 24, .	3.5	3
4	Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Efficizumab in Healthy Chinese Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 30-38.	1.6	6
5	Pharmacokinetics and Pharmacodynamics of Efficizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 351-360.	3.4	55
6	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. <i>Blood</i> , 2021, 137, 2231-2242.	1.4	133
7	Exposure-Bleeding Count Modeling of Efficizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII. <i>Clinical Pharmacokinetics</i> , 2021, 60, 931-941.	3.5	15
8	Low immunogenicity of emicizumab in persons with haemophilia A. <i>Haemophilia</i> , 2021, 27, 984-992.	2.1	26
9	Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Efficizumab in Adult and Pediatric Persons with Hemophilia A. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1611-1625.	3.5	26
10	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. <i>Lancet Haematology</i> , 2019, 6, e295-e305.	4.6	252
11	Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1205-1214.	3.5	1
12	A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. <i>Blood</i> , 2019, 134, 2127-2138.	1.4	241
13	A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Efficizumab in Hemophilia A. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1123-1134.	3.5	65
14	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. <i>New England Journal of Medicine</i> , 2018, 379, 811-822.	27.0	489
15	Immunogenicity of Efficizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies. <i>Blood</i> , 2018, 132, 633-633.	1.4	43
16	Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 537-544.	4.4	4
17	Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist <sc>RG</sc>7697 in people with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1436-1445.	4.4	63
18	The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. <i>Cell Metabolism</i> , 2017, 26, 343-352.e2.	16.2	238

#	ARTICLE	IF	CITATIONS
19	Emicizumab Prophylaxis in Hemophilia A with Inhibitors. <i>New England Journal of Medicine</i> , 2017, 377, 809-818.	27.0	794
20	Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist <sc>RG</sc>7697 after single subcutaneous administration in healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1446-1453.	4.4	39
21	Absence of Pharmacodynamic Interaction Between Inclacumab and Heparin in Healthy Smokers. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 386-392.	1.9	2
22	First-in-man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 611-619.	1.9	38
23	Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of inclacumab in healthy Japanese and Caucasian subjects. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1365-1374.	1.9	4
24	Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects. <i>Clinical Therapeutics</i> , 2015, 37, 2439-2448.	2.5	5
25	Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab – preclinical and clinical studies. <i>Thrombosis Research</i> , 2013, 131, 401-410.	1.7	40
26	Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age. <i>Thrombosis and Haemostasis</i> , 2012, 108, 54-64.	3.4	2
27	Crossover Dose Escalation Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of R1663, an Oral Factor Xa Inhibitor, in Healthy Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 499-510.	2.0	5
28	Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 218-223.	0.6	11
29	Effect of food on the pharmacokinetics and pharmacodynamics of R1663, an oral factor Xa inhibitor, in healthy male volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 566-572.	0.6	2
30	Disease-Drug-Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 735-740.	4.7	216
31	Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2010, 48, 192-199.	0.6	33
32	Drug-Drug Interaction Study of Ketoconazole and Ritonavir-Boosted Saquinavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 609-614.	3.2	14
33	Effect of Saquinavir-Ritonavir on Cytochrome P450 3A4 Activity in Healthy Volunteers Using Midazolam as a Probe. <i>Pharmacotherapy</i> , 2009, 29, 1175-1181.	2.6	24